Pharmacological prospects in the treatment of Duchenne muscular dystrophy.

doi:10.1097/WCO.0b013e328364fbaf

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Pharmacological prospects in the treatment of Duchenne muscular dystrophy.

Current opinion in neurology - 1 Oct 2013

Ruegg Urs T

Abstract excerpt

PURPOSE OF REVIEW: The most encouraging recent advances regarding pharmacological agents for treating Duchenne muscular dystrophy (DMD) are summarized. Emphasis is given to compounds acting downstream of dystrophin, the protein lacking in DMD, on cellular pathways leading to pathological consequences. The author highlights the progress that may have the greatest potential for clinical use in DMD. RECENT FINDINGS:...

Topics

Animals
Dystrophin
Humans
Muscle Fibers, Skeletal
Muscular Dystrophy, Duchenne
Mutation
Signal Transduction
Utrophin

Source

Open in PubMed

Identifiers

PMID: 23995279
DOI: 10.1097/WCO.0b013e328364fbaf

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics